Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 5Carcinoma, Ovarian Epithelial 4Squamous Cell Carcinoma of Head and Neck 3Endometrial Neoplasms 3Breast Neoplasms 3Uterine Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcopenia 1Salivary Gland Neoplasms 1Recurrence 1Primary Breast Cancer 1Peritoneal Neoplasms 1Pathologic Complete Response 1Neutropenia 1Neoplasms, Unknown Primary 1Neoplasms 1NSCLC 1Melanoma 1Malnutrition 1Head and Neck Neoplasms 1

Interventions

olaparib 1Paclitaxel 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Triple Negative Metastatic Breast Cancer × CP protocol × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡